EP1012150A4 - Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders - Google Patents

Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders

Info

Publication number
EP1012150A4
EP1012150A4 EP98924794A EP98924794A EP1012150A4 EP 1012150 A4 EP1012150 A4 EP 1012150A4 EP 98924794 A EP98924794 A EP 98924794A EP 98924794 A EP98924794 A EP 98924794A EP 1012150 A4 EP1012150 A4 EP 1012150A4
Authority
EP
European Patent Office
Prior art keywords
tyrosine kinase
related disorders
protein tyrosine
active against
against protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98924794A
Other languages
German (de)
French (fr)
Other versions
EP1012150A1 (en
Inventor
Gerald Mcmahon
Peng Cho Tang
Laura Kay Shawver
Klaus Peter Hirth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Sugen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sugen LLC filed Critical Sugen LLC
Publication of EP1012150A1 publication Critical patent/EP1012150A1/en
Publication of EP1012150A4 publication Critical patent/EP1012150A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP98924794A 1997-05-19 1998-05-18 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders Withdrawn EP1012150A4 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US4694597P 1997-05-19 1997-05-19
US4708497P 1997-05-19 1997-05-19
US47084P 1997-05-19
US46945P 1997-05-19
US5662397P 1997-08-20 1997-08-20
US56623P 1997-08-20
US6159097P 1997-10-10 1997-10-10
US61590P 1997-10-10
PCT/US1998/010174 WO1998052944A1 (en) 1997-05-19 1998-05-18 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders

Publications (2)

Publication Number Publication Date
EP1012150A1 EP1012150A1 (en) 2000-06-28
EP1012150A4 true EP1012150A4 (en) 2002-05-29

Family

ID=27489113

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98924794A Withdrawn EP1012150A4 (en) 1997-05-19 1998-05-18 Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders

Country Status (5)

Country Link
EP (1) EP1012150A4 (en)
AR (1) AR015685A1 (en)
AU (1) AU7687998A (en)
CA (1) CA2302438A1 (en)
WO (1) WO1998052944A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2362883A1 (en) * 1999-02-12 2000-08-17 Quanam Medical Corporation Alkylating agents for treatment of cellular proliferation
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
WO2000062778A1 (en) 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6903101B1 (en) 2000-08-10 2005-06-07 Bayer Pharmaceuticals Corporation Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
GB0322012D0 (en) * 2003-09-19 2003-10-22 Syngenta Participations Ag Chemical compounds
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
EP1990048A3 (en) * 2007-05-08 2009-05-06 Ulrike Wiebelitz Therapy of benign prostatic hyperplasia (bph)
CA2716448A1 (en) 2008-03-17 2009-09-24 Patrick Brossard Dosing regimen for a selective s1p1 receptor agonist
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
CN108929271B (en) * 2018-06-29 2021-08-31 中国药科大学 Tyrosinase inhibitor and preparation method and application thereof

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073973A1 (en) * 1981-08-24 1983-03-16 BASF Aktiengesellschaft Thiazolyl and isothiazolyl-carboxylic-acid anilides, process for their preparation and their utilization as fungicides
EP0418667A2 (en) * 1989-09-22 1991-03-27 BASF Aktiengesellschaft Carboxylic acid amides
WO1991017748A1 (en) * 1990-05-18 1991-11-28 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
WO1994001408A1 (en) * 1992-07-10 1994-01-20 Laboratoires Glaxo S.A. Anilide derivatives
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
WO1995019169A2 (en) * 1994-01-07 1995-07-20 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancer using inhibitors of platelet derived growth factor receptor
JPH07196637A (en) * 1993-11-24 1995-08-01 Mitsui Toatsu Chem Inc Production of isothiazolecarboxymide derivative
US5476866A (en) * 1993-10-01 1995-12-19 Roussel Uclaf Isoxazoles
WO1996033179A1 (en) * 1995-04-21 1996-10-24 Sugen, Inc. Thioamides derivates and their use as inhibitors of hyper-proliferative cell growth
WO1997011690A2 (en) * 1995-09-29 1997-04-03 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
EP0769296A1 (en) * 1995-10-25 1997-04-23 Hoechst Aktiengesellschaft Use of isoxazole- and crotonamide derivatives for the manufacture of a medicament for the treatment of cancers
WO1997040019A1 (en) * 1996-04-24 1997-10-30 Celltech Therapeutics Limited 5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
WO1998028269A1 (en) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
WO1998057937A2 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Inhibitors of factor xa with a neutral p1 specificity group
WO1999024404A1 (en) * 1997-11-07 1999-05-20 Amgen Inc. Substituted pyridine compounds as anti-inflammatory agents
WO1999043657A1 (en) * 1998-02-27 1999-09-02 F. Hoffmann-La Roche Ag 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists
EP0990645A1 (en) * 1997-05-30 2000-04-05 Nippon Kayaku Kabushiki Kaisha Novel sulfonamide derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0073973A1 (en) * 1981-08-24 1983-03-16 BASF Aktiengesellschaft Thiazolyl and isothiazolyl-carboxylic-acid anilides, process for their preparation and their utilization as fungicides
EP0418667A2 (en) * 1989-09-22 1991-03-27 BASF Aktiengesellschaft Carboxylic acid amides
WO1991017748A1 (en) * 1990-05-18 1991-11-28 Hoechst Aktiengesellschaft Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides, drugs containing these compounds and use of such drugs
WO1994001408A1 (en) * 1992-07-10 1994-01-20 Laboratoires Glaxo S.A. Anilide derivatives
US5342851A (en) * 1992-10-07 1994-08-30 Mcneil-Ppc, Inc. Substituted thiazole derivatives useful as platelet aggregation inhibitors
US5476866A (en) * 1993-10-01 1995-12-19 Roussel Uclaf Isoxazoles
JPH07196637A (en) * 1993-11-24 1995-08-01 Mitsui Toatsu Chem Inc Production of isothiazolecarboxymide derivative
WO1995019169A2 (en) * 1994-01-07 1995-07-20 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancer using inhibitors of platelet derived growth factor receptor
WO1996033179A1 (en) * 1995-04-21 1996-10-24 Sugen, Inc. Thioamides derivates and their use as inhibitors of hyper-proliferative cell growth
WO1997011690A2 (en) * 1995-09-29 1997-04-03 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
EP0769296A1 (en) * 1995-10-25 1997-04-23 Hoechst Aktiengesellschaft Use of isoxazole- and crotonamide derivatives for the manufacture of a medicament for the treatment of cancers
WO1997040019A1 (en) * 1996-04-24 1997-10-30 Celltech Therapeutics Limited 5-aminopyrazoles useful as selective inhibitors of the protein tyrosine kinase p56ick
WO1998028269A1 (en) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company NITROGEN CONTAINING HETEROAROMATICS AS FACTOR Xa INHIBITORS
EP0990645A1 (en) * 1997-05-30 2000-04-05 Nippon Kayaku Kabushiki Kaisha Novel sulfonamide derivatives
WO1998057937A2 (en) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Inhibitors of factor xa with a neutral p1 specificity group
WO1999024404A1 (en) * 1997-11-07 1999-05-20 Amgen Inc. Substituted pyridine compounds as anti-inflammatory agents
WO1999043657A1 (en) * 1998-02-27 1999-09-02 F. Hoffmann-La Roche Ag 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002192888, Database accession no. 1576091 (BRN) *
DATABASE WPI Week 9539, Derwent World Patents Index; AN 1995-299548, XP002192889 *
J. CHEM. SOC. C (1968), (5), 611-14 *
See also references of WO9852944A1 *

Also Published As

Publication number Publication date
AU7687998A (en) 1998-12-11
CA2302438A1 (en) 1998-11-26
WO1998052944A1 (en) 1998-11-26
AR015685A1 (en) 2001-05-16
EP1012150A1 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
HUS1700048I1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
DE69913364D1 (en) Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
ZA9810219B (en) Benzothiazole protein tyrosine kinase inhibitors.
AU8681798A (en) Imidazoquinoxaline protein tyrosine kinase inhibitors
AU8681698A (en) Imidazoquinoxaline protein tyrosine kinase inhibitors
EG23871A (en) Protein kinase c inhibitor
IL127796A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
EP0797581A4 (en) Novel protein tyrosine kinase, jak3
AU8154798A (en) Disease associated protein kinases
AU6882598A (en) Protein kinase inhibitor
EP1012150A4 (en) Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
AU2187301A (en) Protein kinase regulation
AU6163398A (en) Identification of inhibitors of protein tyrosine kinase 2
AU2113899A (en) Human protein kinase molecules
AU2591299A (en) Human protein kinase c inhibitor
GB9803399D0 (en) Protein kinase c
ZA984213B (en) Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders.
AU6546098A (en) Serine/threonine protein kinase
AU6421498A (en) Serine/threonine protein kinase
IL136830A0 (en) Receptor tyrosine kinase, ar-1
AU4750197A (en) A human protein tyrosine kinase
AU1568495A (en) Protein tyrosine kinase a6
EP0800531A4 (en) Novel receptor tyrosine kinases
AU2963395A (en) Mlk receptor tyrosine kinases
AU3097299A (en) Nek1-related protein kinase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000303

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 413/02 A, 7C 07D 231/12 B, 7C 07D 261/18 B, 7C 07D 261/08 B, 7C 07D 413/12 B, 7C 07D 231/14 B, 7C 07D 401/12 B, 7C 07D 407/12 B, 7C 07D 275/02 B, 7C 07D 417/12 B, 7A 61K 31/42 B, 7A 61K 31/415 B, 7A 61K 31/44 B, 7A 61K 31/425 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020411

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20040204

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SUGEN, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060927